The Protocol and proposed Clinical Trial will be a Phase I/II, Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation, Open Label Study to Test the Efficacy and Safety of Homatropine Methylbromide
Oral Suspension on Selected Climacteric Symptoms and Quality of Life in Menopausal Women Not Receiving HRT.
Food and Drug Administration for the company's Abbreviated New Drug Application ("ANDA") for Hydrocodone Bitartrate and Homatropine Methylbromide
Syrup, 5 mg and 1.
Other new launches including Dorzolamide ophthalmic solution, Fluticasone propionate nasal spray, Hydrocodone Bitartrate and Homatropine Methylbromide
syrup, Ofloxacin otic solution, Ciclopirox topical solution, and Calcipotriene solution also contributed to the increase and offset weak cough and flu sales.